JP2009504157A - アルブミン融合タンパク質 - Google Patents

アルブミン融合タンパク質 Download PDF

Info

Publication number
JP2009504157A
JP2009504157A JP2008526056A JP2008526056A JP2009504157A JP 2009504157 A JP2009504157 A JP 2009504157A JP 2008526056 A JP2008526056 A JP 2008526056A JP 2008526056 A JP2008526056 A JP 2008526056A JP 2009504157 A JP2009504157 A JP 2009504157A
Authority
JP
Japan
Prior art keywords
albumin
therapeutic
fragment
variant
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008526056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504157A5 (fr
Inventor
クレイグ・ローゼン
アダム・ベル
ポール・ムーア
ヤング・シ
デイビッド・ラフルーア
マイケル・レアド
ウィリアム・ヘイゼルタイン
ダグラス・ウッズ
ジェイソン・ボック
マニ・サブラマニアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of JP2009504157A publication Critical patent/JP2009504157A/ja
Publication of JP2009504157A5 publication Critical patent/JP2009504157A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
JP2008526056A 2005-08-12 2006-07-31 アルブミン融合タンパク質 Withdrawn JP2009504157A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15
PCT/US2006/029391 WO2007021494A2 (fr) 2005-08-12 2006-07-31 Proteines de fusion avec l'albumine

Publications (2)

Publication Number Publication Date
JP2009504157A true JP2009504157A (ja) 2009-02-05
JP2009504157A5 JP2009504157A5 (fr) 2010-02-04

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008526056A Withdrawn JP2009504157A (ja) 2005-08-12 2006-07-31 アルブミン融合タンパク質

Country Status (13)

Country Link
EP (1) EP1924596A4 (fr)
JP (1) JP2009504157A (fr)
KR (1) KR20080071119A (fr)
AU (1) AU2006280312A1 (fr)
BR (1) BRPI0614761A2 (fr)
CA (1) CA2618476A1 (fr)
EC (1) ECSP088262A (fr)
IL (1) IL189246A0 (fr)
MA (1) MA29836B1 (fr)
MX (1) MX2008001865A (fr)
NO (1) NO20081233L (fr)
TN (1) TNSN08064A1 (fr)
WO (1) WO2007021494A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118042A1 (fr) * 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター Agent médicinal pour l'inhibition de la métastase d'une tumeur maline
JP2013530146A (ja) * 2010-05-21 2013-07-25 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
JP2020517657A (ja) * 2017-04-20 2020-06-18 ノヴォ ノルディスク アー／エス アルブミン融合タンパク質の精製方法
WO2022030580A1 (fr) * 2020-08-06 2022-02-10 国立大学法人宮崎大学 Nouveau dérivé d'adrénomédulline à action prolongée, son procédé de production, et son utilisation pharmaceutique
WO2024080306A1 (fr) * 2022-10-11 2024-04-18 Ｊｃｒファーマ株式会社 Protéine de fusion d'albumine sérique et de protéine physiologiquement active

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
CA2405709A1 (fr) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Proteines fusionnees a l'albumine
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2471363C (fr) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Proteines hybrides d'albumine
MXPA06009072A (es) 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
EP1816201A1 (fr) 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
AU2007258609B2 (en) * 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
BRPI0716744A2 (pt) * 2006-09-14 2016-10-04 Human Genome Sciences Inc proteínas de fusão de albumina
EP2450366A1 (fr) 2007-01-30 2012-05-09 Epivax, Inc. Épitopes de lymphocytes t régulateurs, compositions et utilisations de ceux-ci
RU2567667C2 (ru) 2008-06-13 2015-11-10 Проекто Де Биомедисина Сима, С.Л. Конъюгаты для введения биологически активных соединений
US8323634B2 (en) 2009-01-16 2012-12-04 Teva Pharmaceutical Industries Ltd. Stable formulations of highly concentrated recombinant human albumin-human granulocyte colony stimulating factor
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
EP2396347B1 (fr) 2009-02-11 2017-04-12 Albumedix A/S Variants et conjugés de l'albumine
KR20100100254A (ko) * 2009-03-05 2010-09-15 (주)바이오큐어팜 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물
CN102741280B (zh) * 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
CN104011072B (zh) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 白蛋白变体
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012170969A2 (fr) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Composés pro-coagulants et leurs procédés d'utilisation
GB2515941A (en) 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA201490836A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2780364A2 (fr) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
NZ626945A (en) 2012-01-12 2016-10-28 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
KR20190094480A (ko) 2012-02-15 2019-08-13 바이오버라티브 테라퓨틱스 인크. 재조합 인자 viii 단백질
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
AU2013234299B2 (en) 2012-03-16 2017-06-22 Albumedix Ltd. Albumin variants
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
EP2858659B1 (fr) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Composés pro-coagulants
CN103525695B (zh) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 便携式肾功能检测系统
PT2882450T (pt) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
SI3889173T1 (sl) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc. Optimiran gen dejavnika VIII
EP2956002B1 (fr) 2013-02-16 2017-09-06 Albumedix A/S Modèle pharmacocinétique animal
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3903599A1 (fr) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. Procédés d'inactivation de virus sur colonne
WO2015070014A1 (fr) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Composé de fusion procoagulant
SI3091997T1 (sl) 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc. Himerni proteini faktorja VIII in njihova uporaba
WO2016004113A1 (fr) 2014-06-30 2016-01-07 Biogen Ma Inc. Gène du facteur ix optimisé
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
ES2863278T3 (es) 2015-10-02 2021-10-11 Silver Creek Pharmaceuticals Inc Proteínas terapéuticas biespecíficas para la reparación de tejidos
CN105254766B (zh) * 2015-10-26 2018-10-16 中国航天员科研训练中心 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用
JP7217630B2 (ja) 2016-02-01 2023-02-03 バイオベラティブ セラピューティクス インコーポレイテッド 最適化第ｖｉｉｉ因子遺伝子
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
WO2018082758A1 (fr) 2016-11-04 2018-05-11 Aarhus Universitet Identification et traitement de tumeurs caractérisées par une surexpression du récepteur fc néonatal
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
CA3044838A1 (fr) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Procedes d'induction de tolerance immunitaire a des facteurs de coagulation
EP3562840A1 (fr) 2016-12-16 2019-11-06 Biogen MA Inc. Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé
TW201831521A (zh) 2017-01-31 2018-09-01 美商生物化學醫療公司 因子ｉｘ融合蛋白以及其製備方法及使用方法
KR20200035130A (ko) 2017-08-09 2020-04-01 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
CA3090136A1 (fr) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Utilisation de vecteurs lentiviraux exprimant le facteur viii
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
TW202039855A (zh) 2018-12-06 2020-11-01 美商百歐維拉提夫治療公司 表現因子ｉｘ之慢病毒載體的用途
US20210113634A1 (en) 2019-09-30 2021-04-22 Bioverativ Therapeutics Inc. Lentiviral vector formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471363C (fr) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Proteines hybrides d'albumine
CA2513213C (fr) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Proteines hybrides d'albumine
MXPA06009072A (es) * 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013530146A (ja) * 2010-05-21 2013-07-25 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
JP2017000143A (ja) * 2010-05-21 2017-01-05 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
JP2017225442A (ja) * 2010-05-21 2017-12-28 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
JP2019196365A (ja) * 2010-05-21 2019-11-14 シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッドＳｉｌｖｅｒ Ｃｒｅｅｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 二重特異的融合タンパク質
WO2012118042A1 (fr) * 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター Agent médicinal pour l'inhibition de la métastase d'une tumeur maline
JP2020517657A (ja) * 2017-04-20 2020-06-18 ノヴォ ノルディスク アー／エス アルブミン融合タンパク質の精製方法
WO2022030580A1 (fr) * 2020-08-06 2022-02-10 国立大学法人宮崎大学 Nouveau dérivé d'adrénomédulline à action prolongée, son procédé de production, et son utilisation pharmaceutique
WO2024080306A1 (fr) * 2022-10-11 2024-04-18 Ｊｃｒファーマ株式会社 Protéine de fusion d'albumine sérique et de protéine physiologiquement active

Also Published As

Publication number Publication date
ECSP088262A (es) 2008-05-30
NO20081233L (no) 2008-05-09
MX2008001865A (es) 2008-04-15
WO2007021494A2 (fr) 2007-02-22
BRPI0614761A2 (pt) 2009-05-19
EP1924596A4 (fr) 2009-07-29
AU2006280312A1 (en) 2007-02-22
EP1924596A2 (fr) 2008-05-28
KR20080071119A (ko) 2008-08-01
WO2007021494A3 (fr) 2007-07-26
CA2618476A1 (fr) 2007-02-22
MA29836B1 (fr) 2008-10-03
TNSN08064A1 (en) 2009-07-14
IL189246A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
JP5856131B2 (ja) アルブミン融合タンパク質
JP5568582B2 (ja) アルブミン融合蛋白質
JP5829245B2 (ja) アルブミン融合タンパク質
KR101271635B1 (ko) 알부민 융합 단백질
JP2009504157A (ja) アルブミン融合タンパク質
JP2010503396A (ja) アルブミン融合タンパク質
JP2004506407A (ja) アルブミン融合タンパク質
CN101287750A (zh) 清蛋白融合蛋白
CN1980687B (zh) 清蛋白融合蛋白
CN101557817A (zh) 清蛋白融合蛋白

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091210

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110615